A toothpaste company has quietly killed the entire market research industry and nobody is talking about it. Colgate published a paper showing you can predict real purchase intent at 90% accuracy by simply asking LLMs to roleplay customers. And this is beyond insane. If you ask an AI, "Rate this product from 1 to 5," it gives safe, middle-of-the-road garbage. So researchers invented a method called Semantic Similarity Rating (SSR). Instead of asking the AI for a number, they asked it to roleplay. They gave the LLM a demographic profile. They showed it a product concept. And they asked it to write down its raw, unfiltered thoughts. Then, they used a semantic model to translate those written thoughts into a numerical score. The results are staggering. Tested against 57 real corporate surveys and 9,300 actual human responses, the synthetic AI consumers matched real human buying behavior with 90% reliability. They perfectly mirrored how different age brackets and income levels react to price changes. And they provided detailed, qualitative feedback that was deeper and more critical than what actual humans wrote. This destroys the economics of traditional market research. You don't need to wait a month to see if a product will sell. You can simulate 1,000 hyper-targeted customer interviews overnight. You can A/B test pricing across every demographic instantly.

holy peptides, reta is so good it feels illegal - ozempic hits one receptor - tirzepatide hits two - retatrutide hits three and the third one, glucagon, turns up fat burning while the others turn down appetite the result is the largest weight loss numbers ever recorded for a drug 85 pounds on average at two years, still dropping, no plateau reta is actually making every other obesity drug look like a rough draft we got to the point where biology is adjustable now bio/acc

Retatrutide additional phase 3 results are out, and the data keeps getting better: - 28.3% bodyweight lost on 12mg over 80 weeks (70.3 lbs) - 30.3% at 104 weeks in higher-BMI patients (85 lbs) - 65.3% dropped below the obesity BMI threshold - Knee osteoarthritis pain reduced by up to 75.8% (1 in 8 patients are fully pain-free) - Obstructive sleep apnea significantly improved - Major drops in triglycerides (41%), non-HDL cholesterol (24.2%), and blood pressure - A1C fell up to 2.0% and weight down 16.8% in diabetic patients, in just 40 weeks For those that are unfamiliar, retatrutide now has Phase 3 data showing it reaches well beyond weight loss. It directly treats the complications that have historically required entirely separate medications. This is becoming a new category of medicine, and the data is only getting stronger.

GLP-1s were initially developed to manage type 2 diabetes, but are now showing profound anti-cancer signals across three studies and more than a million patients. The evidence looks promising: (1/11)